Skip to main content

Niraparib

Question for Department of Health and Social Care

UIN 19495, tabled on 21 June 2021

To ask the Secretary of State for Health and Social Care, when NICE plans to publish the outcome of its assessment of the effectiveness of Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer.

Answered on

24 June 2021

In February 2021, the National Institute for Health and Care Excellence issued final guidance that recommends niraparib for use within the Cancer Drugs Fund (CDF) for the maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. Niraparib is now available to eligible National Health Service patients in England through the CDF in line with this recommendation.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.